Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma

Bruno, Karine de Aguiar; Silva, Mário Jorge Sobreira da; Chaves, Gabriela Villaça

doi:10.1080/0284186x.2021.1983210

Cited by 19 publications

(19 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A further search of the reference lists of these articles and relative reviews identified one additional eligible study. Ultimately, 12 studies were included in our study, comprising a total of 2519 patients 7,8,11,24‐32 …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The prognostic impact of myosteatosis on overall survival in gynecological cancer patients: A meta‐analysis and trial sequential analysis

Cao

Yang

Wang

2022

Intl Journal of Cancer

View full text Add to dashboard Cite

Myosteatosis is a novel imaging biomarker for survival in gynecological cancer patients; however, the evidence is inconsistent. This meta‐analysis aims to investigate the impact of myosteatosis on overall survival in the gynecological oncology setting. Three databases (PubMed, EMBASE and Web of Science) were systematically searched for relevant literature up to October 30, 2021. A random‐effects model was used to evaluate the predictive effect of myosteatosis on overall survival in the gynecological cancer population. The Newcastle‐Ottawa Scale was used to assess the methodological quality of the included studies. Trial sequential analysis was used to control the risk of random errors. Twelve studies with a total of 2519 patients were included. Myosteatosis was associated with a 50% increased mortality risk (HR 1.50, 95% CI 1.24‐1.82, P < .001) in gynecological cancer patients. Subgroup analyses stratified by study design, statistical model, treatment, sample size and stage confirmed the predictive value of myosteatosis on survival. However, the prognostic ability of myosteatosis only was held in the American and European populations but lost in Asians. Additionally, myosteatosis was not associated with the increased mortality in endometrial and cervical cancers, except for ovarian cancers. Overall, myosteatosis is a powerful predictor of reduced overall survival in gynecological cancer patients.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Ultimately, 12 studies were included in our study, comprising a total of 2519 patients. 7,8,11,[24][25][26][27][28][29][30][31][32]…”

Section: Publication Qualitymentioning

confidence: 99%

The prognostic impact of myosteatosis on overall survival in gynecological cancer patients: A meta‐analysis and trial sequential analysis

Cao

Yang

Wang

2022

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“… Association of ( A ) body mass index (Kim et al, 2014 [ 49 ], Slaughter et al, 2014 [ 93 ], Fotopoulou et al, 2011 [ 71 ], Zhang et al, 2005 [ 44 ], Aust et al, 2015 [ 59 ], Califano et al, 2013 [ 65 ], Bae et al, 2014 [ 24 ], Orskov et al, 2016 [ 21 ], Pinar et al, 2017 [ 85 ], Kim et al, 2020 [ 50 ], Previs et al, 2014 [ 86 ], Davis et al, 2016 [ 69 ], Kumar et al, 2014 [ 4 ]), ( B ) muscle mass (Chae et al, 2021 [ 66 ], Bronger et al, 2016 [ 63 ], Rutten et al, 2017 [ 89 ], Aust et al, 2015 [ 59 ], Bruno et al, 2021 [ 64 ], Kim et al, 2020 [ 50 ]) and ( C ) muscle density with overall survival Bruno et al, 2021 [ 64 ], Aust et al, 2015 [ 59 ], Ataseven et al, 2018 [ 58 ], Kumar et al, 2016 [ 19 ]. …”

Section: Resultsmentioning

confidence: 99%

Association between Energy Balance-Related Factors and Clinical Outcomes in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis

Stelten

Schofield

Hartman

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: This systematic review and meta-analysis synthesized evidence in patients with ovarian cancer at diagnosis and/or during first-line treatment on; (i) the association of body weight, body composition, diet, exercise, sedentary behavior, or physical fitness with clinical outcomes; and (ii) the effect of exercise and/or dietary interventions. Methods: Risk of bias assessments and best-evidence syntheses were completed. Meta-analyses were performed when ≥3 papers presented point estimates and variability measures of associations or effects. Results: Body mass index (BMI) at diagnosis was not significantly associated with survival. Although the following trends were not supported by the best-evidence syntheses, the meta-analyses revealed that a higher BMI was associated with a higher risk of post-surgical complications (n = 5, HR: 1.63, 95% CI: 1.06–2.51, p = 0.030), a higher muscle mass was associated with a better progression-free survival (n = 3, HR: 1.41, 95% CI: 1.04–1.91, p = 0.030) and a higher muscle density was associated with a better overall survival (n = 3, HR: 2.12, 95% CI: 1.62–2.79, p < 0.001). Muscle measures were not significantly associated with surgical or chemotherapy-related outcomes. Conclusions: The prognostic value of baseline BMI for clinical outcomes is limited, but muscle mass and density may have more prognostic potential. High-quality studies with comprehensive reporting of results are required to improve our understanding of the prognostic value of body composition measures for clinical outcomes. Systematic review registration number: PROSPERO identifier CRD42020163058.

show abstract

“…Weitere Publikationen belegen sogar, dass eine reduzierte Energie-und Nährstoffzufuhr zu Veränderungen des Stoffwechsels führt, welche wiederum einer erfolgreichen Krebstherapie entgegenwirken. Eine Mangelernährung kann auch die von PatientInnen maximal tolerierte Dosis an Zytostatika reduzieren und auf diese Weise zu Unterbrechungen im geplanten Behandlungsablauf führen [17][18][19][20].…”

Section: Mangelernährungunclassified

Supportive Ernährungstherapie für onkologische PatientInnen während der Behandlungsphase

Erickson

Saraç

Frank

2022

Deutsche Zeitschrift für Onkologie

View full text Add to dashboard Cite

ZusammenfassungInsbesondere für onkologische PatientInnen besteht während der Therapiephase ein erhöhtes Risiko für eine reduzierte Flüssigkeits-, Energie- und Nährstoffzufuhr, was wiederum zur Mangelernährung führen kann. Zunehmende Evidenzen belegen den negativen Effekt der Mangelernährung auf Therapieerfolg, Morbidität und Mortalität. Daher sind angemessene ernährungstherapeutische Maßnahmen unabdingbar. Gezielte Ernährungsinterventionen sollen der Ätiologie einer Mangelernährung (wie z. B. Diarrhoe, Übelkeit und Appetitlosigkeit) entgegenwirken und sollten patientenzentriert erfolgen. Hierzu gehört auch die Beseitigung von Fehlinformation und die Vermittlung von praktischen und einsetzbaren Empfehlungen.

show abstract

Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma

Cited by 19 publications

References 69 publications

The prognostic impact of myosteatosis on overall survival in gynecological cancer patients: A meta‐analysis and trial sequential analysis

The prognostic impact of myosteatosis on overall survival in gynecological cancer patients: A meta‐analysis and trial sequential analysis

Association between Energy Balance-Related Factors and Clinical Outcomes in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis

Supportive Ernährungstherapie für onkologische PatientInnen während der Behandlungsphase

Contact Info

Product

Resources

About